TABLE 2.
Cortical excitability measures assessed by the TMS, psychophysical pain measures, and BDNF.
| Fibromyalgia (n = 17) | Major depressive disorder (n = 18) | Healthy control (n = 28) | F | P | |
|---|---|---|---|---|---|
| Motor evocate potential – MEP | 1.28 (±0.25) | 1.56 (±0.52) | 1.45 (±0.43) | 1.750 | 0.183 |
| Intracortical facilitation – ICF | 0.33 (±0.23)a | 1.39 (±1.02)b | 1.14 (±0.27)b | 16.268 | <0.001 |
| Short intracortical inhibition – SICI | 1.03 (±0.50)a | 0.55 (±0.43)b | 0.34 (±0.19)b | 18.701 | <0.001 |
| Cortical silent period – CSP | 67.21 (±19.51)a | 48.58 (±12.21)b | 70.90 (±25.38)a | 8.168 | 0.001 |
| BDNF ng/ml | 49.82 (±16.31)a | 14.12 (±8.86)b | 18.04 (±10.19)b | 50.246 | <0.001 |
| Heat pain threshold (C) | 38.03 (±3.45)a | 39.83 (±3.70)a,b | 42.11 (±3.23)b | 7.903 | 0.001 |
| Change on NPS during CPM TEST | 0.22 (±1.37)a | −0.87 (±1.49)a | −2.54 (±2.46)b | 11.208 | <0.001 |
Data are presented as mean and standard deviation (SD) (n = 63). Different superscripts indicate significant difference among treatment groups after post hoc analysis adjusted by Bonferroni (P < 0.05). Analysis of variance (ANOVA) to compare mean (SD).